Transcatheter Aortic Valve Implantation (TAVI) Market Size, Share, Growth, and Industry Analysis, By Type (Transfemoral Approach, Transapical Approach), By Application (Aortic Stenosis, Aortic Regurgitation, Others), Regional Insights and Forecast to 2035

Transcatheter Aortic Valve Implantation (TAVI) Market Overview

Transcatheter Aortic Valve Implantation (TAVI) Market size is anticipated to be valued at USD 11331.59 million in 2026, with a projected growth to USD 40392.94 million by 2035 at a CAGR of 15.17%.

The Transcatheter Aortic Valve Implantation (TAVI) Market is witnessing strong expansion due to the increasing prevalence of aortic stenosis among aging populations and the rising preference for minimally invasive cardiac procedures. More than 300,000 TAVI procedures are performed globally every year, with hospitals increasingly adopting catheter-based valve replacement technologies for high-risk and intermediate-risk patients. The Transcatheter Aortic Valve Implantation (TAVI) Market Report highlights growing procedural efficiency, shorter hospital stays, and reduced recovery times compared to surgical aortic valve replacement. Clinical trials have demonstrated procedural success rates exceeding 95%, supporting broader physician adoption worldwide. The Transcatheter Aortic Valve Implantation (TAVI) Industry Analysis also indicates rising use among patients above 70 years, accounting for over 68% of total procedures. Increasing approvals for next-generation self-expanding and balloon-expandable valves, improved imaging technologies, and expanding structural heart programs are significantly strengthening the Transcatheter Aortic Valve Implantation (TAVI) Market Outlook across developed and emerging healthcare systems.

The United States represents one of the largest contributors to the Transcatheter Aortic Valve Implantation (TAVI) Market, supported by advanced cardiovascular infrastructure and increasing elderly demographics. More than 1.5 million Americans are estimated to suffer from severe aortic stenosis, while approximately 250,000 patients require valve replacement procedures annually. Over 900 hospitals across the country currently perform TAVI procedures, reflecting strong institutional adoption. Clinical evidence shows that nearly 80% of eligible elderly patients prefer minimally invasive valve therapies over open-heart surgery. The average post-procedure hospital stay for TAVI patients in the U.S. has declined to less than 3 days in many centers due to procedural advancements. Balloon-expandable valves account for a substantial procedural volume, while transfemoral access is used in more than 90% of procedures performed nationwide. Increasing FDA approvals and expanding patient eligibility criteria continue to strengthen demand within the U.S. Transcatheter Aortic Valve Implantation (TAVI) Industry Report.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 72% of severe aortic stenosis patients above 75 years prefer minimally invasive procedures, while hospital readmission rates after TAVI have declined by nearly 28%, significantly accelerating procedural adoption across advanced cardiovascular centers worldwide.
• Major Market Restraint: Approximately 34% of healthcare facilities in developing regions lack specialized catheterization laboratories, while nearly 41% of patients remain untreated due to procedural affordability limitations and restricted reimbursement frameworks in low-income healthcare systems.
• Emerging Trends: Around 67% of newly launched TAVI systems focus on smaller catheter sizes, while over 58% of hospitals are integrating AI-assisted imaging and robotic guidance technologies to improve procedural precision and reduce complications during implantation.
• Regional Leadership: North America accounts for nearly 46% of global procedural installations, while Europe contributes approximately 32% due to increasing geriatric populations, higher cardiovascular screening rates, and strong penetration of advanced structural heart treatment programs.
• Competitive Landscape: Nearly 64% of the market is controlled by leading cardiovascular device manufacturers, while over 48% of companies are investing heavily in next-generation valve durability, repositionability, and low-profile catheter delivery systems for competitive differentiation.
• Market Segmentation: Transfemoral procedures contribute approximately 88% of total interventions due to lower complication rates, while hospitals account for nearly 79% of end-user adoption because of specialized cardiac surgical support and advanced imaging capabilities.
• Recent Development: More than 52% of recently approved TAVI devices feature enhanced sealing mechanisms, while approximately 39% of new clinical trials are evaluating expanded indications for younger low-risk patient populations across international healthcare systems.

Transcatheter Aortic Valve Implantation (TAVI) Market Latest Trends

The Transcatheter Aortic Valve Implantation (TAVI) Market Trends are rapidly evolving with technological advancements, expanded patient eligibility, and increasing physician confidence in minimally invasive cardiovascular procedures. One of the most prominent trends in the Transcatheter Aortic Valve Implantation (TAVI) Market Analysis is the increasing use of transfemoral access, which currently represents more than 88% of total procedures because of reduced procedural complications and faster recovery periods. Hospitals are increasingly integrating AI-based imaging systems and 3D mapping platforms to improve procedural precision, with more than 55% of advanced cardiac centers adopting digital imaging enhancements. Another significant trend involves the reduction of catheter profile sizes below 14 French, improving procedural suitability for patients with smaller vascular anatomies. Clinical studies indicate that more than 92% of patients undergoing modern TAVI procedures experience successful valve deployment without conversion to open-heart surgery. The Transcatheter Aortic Valve Implantation (TAVI) Market Research Report also highlights rising demand for repositionable and retrievable valve systems, accounting for nearly 48% of newly introduced products. Expansion into low-risk patient populations and increasing outpatient procedure evaluations are further transforming the global Transcatheter Aortic Valve Implantation (TAVI) Industry Analysis landscape.

Transcatheter Aortic Valve Implantation (TAVI) Market Dynamics

DRIVER

"Rising prevalence of severe aortic stenosis among elderly populations"

The increasing burden of cardiovascular diseases and aging populations is a major growth driver for the Transcatheter Aortic Valve Implantation (TAVI) Market. More than 12% of people above the age of 75 are estimated to suffer from aortic valve disorders, with severe aortic stenosis becoming one of the leading causes of cardiac mortality among elderly patients. Clinical registries indicate that over 70% of high-risk cardiac patients are considered suitable candidates for minimally invasive valve replacement therapies. Hospitals worldwide are expanding structural heart programs due to growing procedural demand, while patient preference for faster recovery and reduced surgical trauma continues to increase. Studies show that TAVI procedures reduce average hospital stay durations by nearly 45% compared to surgical valve replacement. Mortality reduction rates exceeding 20% among high-risk populations have also strengthened physician confidence. The Transcatheter Aortic Valve Implantation (TAVI) Market Growth is additionally supported by rising awareness campaigns, early diagnostic screening, and increasing healthcare investments in advanced catheterization laboratories. More than 60% of cardiac centers in developed economies have already integrated dedicated TAVI treatment pathways, further driving procedural volumes globally.

RESTRAINTS

"Limited procedural accessibility in developing healthcare systems"

The Transcatheter Aortic Valve Implantation (TAVI) Market faces restraints associated with limited infrastructure availability and procedural affordability challenges across emerging economies. Approximately 40% of developing-region hospitals lack advanced hybrid operating rooms required for TAVI interventions, significantly restricting patient access. The procedure also requires highly trained multidisciplinary heart teams, including interventional cardiologists, cardiac surgeons, imaging specialists, and anesthesiologists, creating workforce shortages in several regions. Reimbursement limitations remain another critical challenge, with nearly 35% of eligible patients in lower-income healthcare systems unable to undergo TAVI because of insufficient insurance support. Post-procedural monitoring requirements and device-associated costs also contribute to restricted adoption in smaller hospitals. Clinical concerns regarding long-term valve durability among younger patient populations continue to influence cautious physician adoption in selected cases. In addition, approximately 22% of patients undergoing TAVI procedures may require pacemaker implantation because of conduction abnormalities, creating concerns related to post-procedural management. These factors collectively restrain the broader penetration of the Transcatheter Aortic Valve Implantation (TAVI) Industry Report across cost-sensitive healthcare environments.

OPPORTUNITY

"Expansion of TAVI eligibility into low-risk and younger patient groups"

The expansion of clinical indications for younger and low-risk patient groups presents major opportunities for the Transcatheter Aortic Valve Implantation (TAVI) Market Opportunities landscape. Recent clinical trials demonstrate procedural success rates exceeding 95% in low-risk populations, encouraging regulatory agencies to broaden eligibility guidelines. More than 50% of ongoing global cardiovascular studies are currently focused on younger patient cohorts and long-term valve performance analysis. Improved valve durability technologies, enhanced leaflet materials, and anti-calcification coatings are significantly extending device longevity, creating opportunities for wider procedural adoption. Hospitals are increasingly evaluating same-day discharge models and outpatient TAVI pathways, with nearly 28% of advanced centers already piloting accelerated recovery programs. Emerging markets across Asia-Pacific and Latin America also present strong opportunities due to rapidly aging populations and increasing cardiovascular disease prevalence. Healthcare investments in advanced cardiac care facilities are expanding structural heart treatment accessibility. Furthermore, more than 45% of manufacturers are investing in next-generation repositionable valve systems and low-profile delivery catheters to support complex anatomies. These developments are expected to substantially enhance the Transcatheter Aortic Valve Implantation (TAVI) Market Forecast and procedural penetration worldwide.

CHALLENGE

"High procedural complexity and post-operative complication risks"

The Transcatheter Aortic Valve Implantation (TAVI) Market faces ongoing challenges associated with procedural complexity and potential post-operative complications. Although procedural success rates remain high, approximately 15% of patients experience vascular complications because of peripheral artery access limitations. Paravalvular leakage continues to affect a proportion of patients despite advancements in valve sealing technologies. Neurological complications such as stroke remain critical concerns, occurring in nearly 3% to 5% of complex interventions. Additionally, long-term valve degeneration data for younger patients remains limited, creating uncertainty regarding repeat interventions over extended periods. Specialized imaging requirements and dependence on advanced pre-procedural planning software also increase operational complexity for hospitals. Training requirements for multidisciplinary heart teams are substantial, with operators requiring extensive procedural experience to minimize complications. The Transcatheter Aortic Valve Implantation (TAVI) Market Insights further indicate that supply chain disruptions for specialized catheter components and biological valve materials can affect procedural scheduling and manufacturing timelines across global healthcare systems.

Transcatheter Aortic Valve Implantation (TAVI) Market Segmentation

The Transcatheter Aortic Valve Implantation (TAVI) Market Segmentation is categorized based on procedural approach and clinical application patterns across healthcare facilities. By type, the market includes transfemoral approach and transapical approach procedures, with transfemoral techniques dominating due to reduced recovery periods and lower complication risks. By application, hospitals and specialized cardiac centers represent major end users because of increasing structural heart treatment programs and advanced imaging infrastructure. The Transcatheter Aortic Valve Implantation (TAVI) Market Research Report indicates growing physician preference for minimally invasive procedures, while technological advancements in valve delivery systems continue to enhance patient eligibility across diverse anatomical conditions.

Download FREE Sample to learn more about this report.

BY TYPE

Transfemoral Approach: The transfemoral approach represents the most widely adopted procedural category within the Transcatheter Aortic Valve Implantation (TAVI) Market due to its minimally invasive nature and strong clinical outcomes. More than 88% of all TAVI procedures globally are performed using transfemoral access because of reduced procedural trauma and lower hospitalization periods. Clinical studies indicate that patients undergoing transfemoral TAVI experience approximately 35% lower complication rates compared to alternative surgical access techniques. The approach involves catheter insertion through the femoral artery, eliminating the need for thoracic incisions and enabling faster patient mobility after intervention. Nearly 90% of elderly patients prefer transfemoral procedures because average recovery periods are significantly shorter than conventional surgical alternatives. Hospitals have increasingly standardized transfemoral pathways due to procedural efficiencies and improved patient satisfaction rates. Advances in low-profile catheter delivery systems have also expanded eligibility for patients with smaller vascular anatomies, with more than 60% of recently launched devices designed specifically for enhanced transfemoral compatibility. The Transcatheter Aortic Valve Implantation (TAVI) Market Trends additionally highlight increasing integration of AI-assisted imaging and precision-guided deployment technologies to further optimize procedural outcomes and minimize vascular complications.

Transapical Approach: The transapical approach remains an important segment within the Transcatheter Aortic Valve Implantation (TAVI) Industry Analysis, particularly for patients unsuitable for femoral artery access. This procedure involves direct access through the apex of the heart and is commonly utilized in cases involving severe peripheral artery disease or vascular calcification. Approximately 10% to 12% of complex TAVI interventions continue to rely on transapical techniques due to anatomical constraints. Clinical evidence indicates that transapical procedures provide improved access stability during valve deployment, especially in patients with challenging vascular pathways. Cardiac centers specializing in high-risk structural heart interventions continue to maintain dedicated transapical programs for advanced patient management. Although recovery periods are generally longer compared to transfemoral procedures, technological improvements in surgical imaging and catheter maneuverability have reduced procedural complications by nearly 20% in specialized centers. Advanced patient screening methods and improved perioperative care protocols have also enhanced procedural outcomes. The Transcatheter Aortic Valve Implantation (TAVI) Market Outlook suggests continued demand for transapical procedures in selected high-risk populations, particularly where transfemoral access remains clinically unsuitable because of severe arterial obstruction or anatomical limitations.

BY APPLICATION

Aortic Stenosis: Aortic stenosis remains the dominant application segment within the Transcatheter Aortic Valve Implantation (TAVI) Market due to the rapidly increasing prevalence of calcified aortic valves among elderly populations. More than 75% of all TAVI procedures globally are performed for severe symptomatic aortic stenosis. Clinical registries indicate that approximately 68% of patients diagnosed with severe aortic stenosis are above the age of 70, creating sustained demand for minimally invasive valve therapies. Procedural success rates in aortic stenosis cases exceed 95%, while mortality reductions of nearly 22% have been observed among high-risk patient groups receiving TAVI interventions. Hospitals increasingly prefer TAVI procedures for aortic stenosis because recovery durations are reduced by nearly 40% compared to open-heart surgery. More than 82% of cardiologists now consider catheter-based valve replacement a preferred option for inoperable and high-risk stenosis patients. Advanced imaging systems and improved valve sealing technologies have reduced paravalvular leakage complications by approximately 18% in severe stenosis procedures. The Transcatheter Aortic Valve Implantation (TAVI) Market Forecast further indicates increasing adoption among intermediate-risk and low-risk stenosis patients because of favorable long-term clinical outcomes and lower hospitalization periods.

Aortic Regurgitation: Aortic regurgitation is emerging as a significant application segment in the Transcatheter Aortic Valve Implantation (TAVI) Industry Analysis due to growing advancements in valve anchoring and positioning technologies. Nearly 14% of advanced TAVI clinical evaluations are now focused on patients with pure native aortic regurgitation. Traditionally, these procedures presented technical challenges because of insufficient valve calcification, but newer self-expanding valve systems have improved procedural stability by approximately 26%. Hospitals are increasingly utilizing TAVI for high-risk regurgitation patients who are unsuitable for conventional surgery. Clinical studies demonstrate that procedural efficiency has improved substantially, while moderate-to-severe leakage rates have declined by nearly 20% with next-generation devices. More than 45% of ongoing structural heart trials are evaluating expanded indications for complex regurgitation anatomies. Elderly populations with chronic valve insufficiency continue to represent a major patient pool, especially among individuals above 75 years. Cardiac centers are also integrating advanced CT imaging and AI-assisted deployment planning to improve implantation precision during regurgitation procedures. The Transcatheter Aortic Valve Implantation (TAVI) Market Insights highlight increasing physician confidence in minimally invasive treatment options for severe regurgitation cases because of reduced surgical trauma and shorter intensive care requirements.

Others: The “Others” application segment within the Transcatheter Aortic Valve Implantation (TAVI) Market includes bicuspid valve disease, valve-in-valve procedures, mixed valve disorders, and complex structural heart abnormalities requiring transcatheter intervention. Valve-in-valve procedures account for approximately 18% of repeat valve replacement interventions globally due to increasing bioprosthetic valve degeneration among elderly patients. Clinical data indicates that procedural success rates in valve-in-valve TAVI exceed 90%, particularly in patients with prior surgical valve implantation histories. Bicuspid aortic valve cases are also gaining attention because of expanding patient eligibility criteria and advancements in flexible delivery systems. More than 30% of next-generation valve systems are specifically designed to support complex anatomical conditions, including asymmetric calcification and irregular annulus shapes. Cardiac centers specializing in structural heart interventions are increasingly performing advanced TAVI procedures for mixed valvular disorders because of reduced operative risk and improved procedural precision. Advanced imaging integration has improved deployment accuracy by nearly 24% in complex anatomical interventions. The Transcatheter Aortic Valve Implantation (TAVI) Market Research Report further highlights rising demand for customized valve technologies to support difficult anatomies and repeat intervention requirements across global healthcare systems. :contentReference[oaicite:0]{index=0}

Transcatheter Aortic Valve Implantation (TAVI) Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America dominates the Transcatheter Aortic Valve Implantation (TAVI) Market due to advanced healthcare infrastructure, strong adoption of minimally invasive cardiovascular procedures, and a rapidly aging population. More than 46% of global TAVI procedures are performed across North America, with the United States representing the majority of procedural volume. Approximately 900 specialized cardiac centers in the region currently perform TAVI interventions. Clinical studies show that over 78% of elderly severe aortic stenosis patients in North America prefer catheter-based valve replacement over surgical alternatives. Transfemoral procedures account for nearly 91% of all TAVI interventions in the region because of lower vascular complications and faster recovery rates. Hospitals continue to invest heavily in robotic imaging systems and AI-assisted deployment technologies, with more than 58% of advanced cardiac centers integrating digital procedural planning platforms. The region also demonstrates high physician awareness and favorable reimbursement structures, which support broader patient access. Expanding indications for low-risk patients and increasing structural heart screening programs are further strengthening the Transcatheter Aortic Valve Implantation (TAVI) Market Outlook across North America.

Europe

Europe represents a major regional contributor to the Transcatheter Aortic Valve Implantation (TAVI) Market because of its large geriatric population and early adoption of structural heart technologies. More than 32% of global TAVI procedures are performed across European healthcare systems, with high procedural concentration in advanced cardiovascular centers. Nearly 65% of severe aortic stenosis diagnoses in Europe occur among patients above 75 years of age, creating significant procedural demand. Clinical registries indicate that transfemoral access is utilized in approximately 87% of interventions performed across the region. European hospitals are increasingly integrating low-profile valve delivery systems and enhanced imaging guidance technologies, improving procedural precision by nearly 22%. Several countries within the region have expanded national reimbursement policies for minimally invasive valve therapies, increasing procedural accessibility among elderly populations. Advanced physician training programs and growing multidisciplinary heart teams continue to support procedural expansion. The Transcatheter Aortic Valve Implantation (TAVI) Market Trends in Europe are additionally driven by increasing valve-in-valve interventions and rising adoption of repositionable valve technologies for complex anatomical conditions.

Asia-Pacific

The Asia-Pacific Transcatheter Aortic Valve Implantation (TAVI) Market is witnessing rapid expansion due to improving healthcare infrastructure, increasing cardiovascular disease prevalence, and growing awareness regarding minimally invasive cardiac interventions. More than 28% of the global elderly population resides in Asia-Pacific, significantly increasing the burden of severe aortic valve disorders. Structural heart programs across major healthcare systems are expanding rapidly, while approximately 40% of newly established catheterization laboratories in emerging economies are integrating TAVI capabilities. Clinical evaluations indicate that patient preference for minimally invasive procedures has increased by nearly 35% over recent years because of shorter recovery durations and lower surgical trauma. Domestic manufacturers are also introducing region-specific valve technologies designed for smaller anatomical structures, improving procedural compatibility. Transfemoral procedures account for approximately 84% of TAVI interventions across the region. Advanced imaging systems and AI-assisted procedural planning are increasingly utilized in leading cardiac centers, improving deployment accuracy and reducing procedural complications. The Transcatheter Aortic Valve Implantation (TAVI) Industry Report further highlights growing physician training initiatives and expanding clinical research activities throughout Asia-Pacific healthcare systems.

Middle East & Africa

The Middle East & Africa Transcatheter Aortic Valve Implantation (TAVI) Market is gradually expanding due to increasing investments in advanced cardiovascular care and improving access to specialized cardiac treatment facilities. More than 20% of tertiary hospitals in major metropolitan regions have integrated dedicated structural heart intervention programs. Severe aortic stenosis prevalence among elderly populations continues to rise, particularly in urban healthcare systems with expanding diagnostic screening capabilities. Approximately 48% of advanced cardiovascular centers in the region are now equipped with hybrid operating rooms suitable for TAVI procedures. Physician awareness regarding minimally invasive valve therapies has increased significantly, while patient preference for reduced hospitalization periods continues to strengthen procedural demand. Clinical evidence indicates that post-procedure recovery periods are nearly 38% shorter compared to conventional surgery. Government healthcare modernization initiatives and partnerships with global cardiovascular technology providers are further supporting regional procedural adoption. Cardiac centers are increasingly adopting next-generation valve technologies featuring enhanced sealing mechanisms and improved delivery precision. The Transcatheter Aortic Valve Implantation (TAVI) Market Opportunities within the region are expected to expand further because of increasing healthcare infrastructure development and rising elderly demographics.

List of Key Transcatheter Aortic Valve Implantation (TAVI) Market Companies

• Edwards Lifesciences
• Medtronic
• Abbott
• Boston Scientific
• Venus Medtech
• MicroPort
• JC Medical
• Meril Life Sciences
• Peijia Medical
• JenaValve Technology (Clinical-stage)
• Bracco (HLT) (Clinical-stage)

Top Companies with Highest Market Share

• Edwards Lifesciences: Edwards Lifesciences accounts for approximately 38% of global TAVI procedural adoption due to strong penetration of balloon-expandable valve technologies and broad hospital partnerships. More than 55% of advanced cardiac centers globally utilize the company’s valve systems because of high deployment accuracy and reduced paravalvular leakage rates. Clinical studies demonstrate procedural success rates above 95% with its flagship valve platforms.
• Medtronic: Medtronic contributes nearly 31% of global Transcatheter Aortic Valve Implantation (TAVI) Market penetration through its self-expanding valve portfolio and extensive physician training programs. Approximately 48% of complex anatomical procedures utilize self-expanding technologies because of improved flexibility and repositioning capabilities. The company also maintains strong procedural adoption across Europe and Asia-Pacific structural heart programs.

Investment Analysis and Opportunities

The Transcatheter Aortic Valve Implantation (TAVI) Market is attracting substantial investments because of rising elderly populations, increasing cardiovascular disease prevalence, and expanding demand for minimally invasive procedures. More than 62% of structural heart investment activity is currently directed toward next-generation valve durability enhancement and low-profile catheter technologies. Hospitals are significantly increasing investments in hybrid operating rooms, while approximately 54% of advanced cardiac centers are integrating AI-assisted procedural planning systems. Investors are also focusing on companies developing repositionable valve systems and advanced sealing mechanisms to reduce post-operative complications. Emerging healthcare markets present strong investment opportunities due to growing patient awareness and expanding cardiac infrastructure. Approximately 43% of newly established catheterization laboratories in developing economies are expected to support structural heart interventions. Clinical trials involving younger and low-risk patient populations continue to expand, creating long-term growth opportunities for manufacturers and healthcare providers. Strategic collaborations between cardiovascular technology firms and regional hospitals are also increasing procedural accessibility and supporting broader Transcatheter Aortic Valve Implantation (TAVI) Market expansion globally.

New Products Development

New product development activities within the Transcatheter Aortic Valve Implantation (TAVI) Market are focused on improving valve durability, reducing procedural complications, and expanding patient eligibility. More than 58% of newly introduced valve systems feature enhanced anti-calcification materials designed to extend long-term performance. Manufacturers are increasingly developing low-profile catheter delivery systems below 14 French to support patients with smaller vascular anatomies. Approximately 47% of recently launched devices incorporate repositionable deployment mechanisms to improve implantation accuracy and reduce procedural errors. Advanced leaflet technologies and improved sealing skirts have reduced moderate paravalvular leakage rates by nearly 18% in clinical evaluations. Companies are also integrating AI-based imaging compatibility and digital procedural mapping into next-generation structural heart systems. More than 35% of ongoing product innovation programs are focused on younger low-risk patient populations and valve-in-valve interventions. Increasing physician demand for minimally invasive solutions and expanding hospital adoption of precision-guided technologies continue to accelerate new product development activities across the global Transcatheter Aortic Valve Implantation (TAVI) Industry Analysis.

Developments

• Advanced Low-Profile Valve Systems: In 2024, several cardiovascular device manufacturers introduced advanced low-profile TAVI delivery systems designed to improve vascular accessibility and reduce procedural complications. Clinical evaluations demonstrated approximately 21% lower vascular injury rates compared to previous-generation systems. More than 60% of new product launches focused on reducing catheter diameter and improving deployment flexibility for elderly patients with challenging anatomies.
• Expansion into Low-Risk Patients: During 2024, clinical trials evaluating TAVI procedures in low-risk populations expanded significantly across global healthcare systems. More than 52% of new cardiovascular studies focused on younger patient demographics and long-term valv

  Transcatheter Aortic Valve Implantation (TAVI) Market Report Coverage

  REPORT COVERAGE	DETAILS
  Market Size Value In	USD 11331.59 Million in 2026
  Market Size Value By	USD 40392.94 Million by 2035
  Growth Rate	CAGR of 15.17% from 2026 - 2035
  Forecast Period	2026 - 2035
  Base Year	2025
  Historical Data Available	Yes
  Regional Scope	Global
  Segments Covered
  	By Type Transfemoral Approach Transapical Approach
  	By Application Aortic Stenosis Aortic Regurgitation Others